The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2023 | Supporting NGS for pancreatic ductal adenocarcinoma
Philip Philip, MD, PhD, FRCP, Wayne State University School of Medicine/Henry Ford Health, Detroit, MI, describes the benefits of next-generation sequencing (NGS) for patients with pancreatic ductal adenocarcinoma (PDAC). There are very few treatment options available for PDAC, especially for patients who progress on first-line therapies. NGS will spur the development of novel therapies, and personalized medicine. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
